Moloney GM, Long-Smith CM, Murphy A, et al
Phase 3 (21 Days) Deep Tissue Repair: Complete healing of joint micro-injuries occurs as new, healthy tissue regenerates, restoring long-term joint health
Three drugs are in Phase 2 trials: AstraZenecas GCGR x GLP-1R dual agonist, Cotadutide
doi:10.1007/s12011-019-01963-5 Mahmoodianfard S, Vafa M, Golgiri F, et al
Furthermore, early safety trials that included kidney outcomes as secondary endpoints hinted at potential renal benefits associated with these medication classes
Review the full product information and discuss this information and any questions you have with your doctor or other health care provider